Prostate Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight’s “Prostate Cancer Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Prostate Cancer pipeline landscapes.
The report comprises Prostate Cancer pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Prostate Cancer pipeline products.
Prostate Cancer Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of the male reproductive system. Prostate cancer is the 3rdmost prevalent type of cancer in the US and the fourth most common worldwide.
Some of the key takeaways from the Prostate Cancer Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as AstraZeneca/Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Advantagene or Candel Therapeutics, Merck Sharp & Dohme, etc., are developing therapies for the treatment of Prostate Cancer.
-
Emerging therapies such as Lynparza, Opdivo, Lutathera, Relugolix, Niraparib, HC-1119, Ipatasertib, Talazoparib, Rucaparib, ProstAtak, Keytruda, are expected to have a significant impact on the Prostate Cancer market in the coming years.
Get an overview of pipeline landscape @ Prostate Cancer Clinical Trials Analysis
Prostate Cancer Pipeline Therapies along with Key Players:
-
Lynparza :AstraZeneca/Merck Sharp & Dohme
-
Opdivo: Bristol-Myers Squibb
-
Lutathera: Novartis
-
Relugolix: Myovant Sciences
-
Niraparib: Janssen Research & Development
-
HC-1119: Hinova Pharmaceuticals USA
-
Ipatasertib: Hoffmann-La Roche
-
Talazoparib: Pfizer/Astellas Pharma
-
Rucaparib: Clovis Oncology
-
ProstAtak: Advantagene or Candel Therapeutics
-
Keytruda: Merck Sharp & Dohme
Scope of Prostate Cancer Pipeline Drug Insight
-
Coverage: Global
-
Major Players: AstraZeneca/Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Advantagene or Candel Therapeutics, Merck Sharp & Dohme, and others.
-
Pipeline Therapies: Lynparza, Opdivo, Lutathera, Relugolix, Niraparib, HC-1119, Ipatasertib, Talazoparib, Rucaparib, ProstAtak, Keytruda, and others.
Table of Contents
|
1 |
Prostate Cancer Report Introduction |
|
2 |
Prostate Cancer Executive Summary |
|
3 |
Prostate Cancer Overview |
|
4 |
Prostate Cancer- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Prostate Cancer Pipeline Therapeutics |
|
6 |
Prostate Cancer Late Stage Products (Phase II/III) |
|
7 |
Prostate Cancer Mid Stage Products (Phase II) |
|
8 |
Prostate Cancer Early Stage Products (Phase I) |
|
9 |
Prostate Cancer Preclinical Stage Products |
|
10 |
Prostate Cancer Therapeutics Assessment |
|
11 |
Prostate Cancer Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Prostate Cancer Key Companies |
|
14 |
Prostate Cancer Key Products |
|
15 |
Prostate Cancer Unmet Needs |
|
16 |
Prostate Cancer Market Drivers and Barriers |
|
17 |
Prostate Cancer Future Perspectives and Conclusion |
|
18 |
Prostate Cancer Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Prostate Cancer Drugs Pipeline Report
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
